Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Overview of attention for article published in Vascular Health and Risk Management, September 2017

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 67 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors

Article in Current Atherosclerosis Reports (October 2021)

How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators.

Article in Panminerva Medica (June 2021)

Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation

Article in Pharmacological Research (May 2021)